Equashield is a leading global provider of closed system transfer devices (CSTDs) designed to protect healthcare professionals from exposure to hazardous drugs. With a relentless focus on quality, safety, and ease of use, Equashield’s product offerings are based on proprietary technologies spanning both manual CSTDs and novel automated compounding solutions – including a next-generation automated compounding system utilising artificial intelligence to deliver superior performance.
Company Background
Since its founding in 2009, Equashield has recorded robust growth fuelled by continued product innovation, high customer satisfaction, and the pioneering of new technological solutions for handling hazardous drugs
Products are sold across five continents Equashield is a leading CSTD provider in the largest global market, the United States
Vision & Outlook
Opportunity to leverage Equashield’s technological edge to further accelerate growth
Pipeline of innovative compounding technologies, including a novel automated drug compounding system
Vast potential of compounding automation to improve safety and efficiency in the handling of hazardous drugs

SECTOR
Healthcare
REVENUES 2022
EUR 100 million
EMPLOYEES
450
OWNERSHIP
Fund XI
INVESTMENT DATE
2022
HEAD OFFICE
Tefen, Israel